Stable Protein Sialylation in Physcomitrella
Overview
Authors
Affiliations
Recombinantly produced proteins are indispensable tools for medical applications. Since the majority of them are glycoproteins, their -glycosylation profiles are major determinants for their activity, structural properties and safety. For therapeutical applications, a glycosylation pattern adapted to product and treatment requirements is advantageous. (Physcomitrella, moss) is able to perform highly homogeneous complex-type -glycosylation. Additionally, it has been glyco-engineered to eliminate plant-specific sugar residues by knock-out of the β1,2-xylosyltransferase and α1,3-fucosyltransferase genes (Δxt/ft). Furthermore, Physcomitrella meets wide-ranging biopharmaceutical requirements such as GMP compliance, product safety, scalability and outstanding possibilities for precise genome engineering. However, all plants, in contrast to mammals, lack the capability to perform -glycan sialylation. Since sialic acids are a common terminal modification on human glycans, the property to perform -glycan sialylation is highly desired within the plant-based biopharmaceutical sector. In this study, we present the successful achievement of protein -glycan sialylation in stably transformed Physcomitrella. The sialylation ability was achieved in a Δxt/ft moss line by stable expression of seven mammalian coding sequences combined with targeted organelle-specific localization of the encoded enzymes responsible for the generation of β1,4-galactosylated acceptor -glycans as well as the synthesis, activation, transport and transfer of sialic acid. Production of free (Neu5Ac) and activated (CMP-Neu5Ac) sialic acid was proven. The glycosidic anchor for the attachment of terminal sialic acid was generated by the introduction of a chimeric human β1,4-galactosyltransferase gene under the simultaneous knock-out of the gene encoding the endogenous β1,3-galactosyltransferase. Functional complex-type glycan sialylation was confirmed via mass spectrometric analysis of a stably co-expressed recombinant human protein.
Differential prolyl hydroxylation by six Physcomitrella prolyl-4 hydroxylases.
Rempfer C, Hoernstein S, van Gessel N, Graf A, Spiegelhalder R, Bertolini A Comput Struct Biotechnol J. 2024; 23:2580-2594.
PMID: 39021582 PMC: 11252719. DOI: 10.1016/j.csbj.2024.06.014.
Leprovost S, Plasson C, Balieu J, Walet-Balieu M, Lerouge P, Bardor M Plant Biotechnol J. 2024; 22(11):3018-3027.
PMID: 38968612 PMC: 11500980. DOI: 10.1111/pbi.14424.
Uetz P, Goritzer K, Vergara E, Melnik S, Grunwald-Gruber C, Figl R Front Bioeng Biotechnol. 2024; 12:1329018.
PMID: 38511130 PMC: 10953500. DOI: 10.3389/fbioe.2024.1329018.
Multifactorial analysis of terminator performance on heterologous gene expression in Physcomitrella.
Niederau P, Egle P, Willig S, Parsons J, Hoernstein S, Decker E Plant Cell Rep. 2024; 43(2):43.
PMID: 38246952 PMC: 10800305. DOI: 10.1007/s00299-023-03088-5.
Parthiban S, Vijeesh T, Gayathri T, Shanmugaraj B, Sharma A, Sathishkumar R Front Plant Sci. 2023; 14:1252166.
PMID: 38034587 PMC: 10684705. DOI: 10.3389/fpls.2023.1252166.